Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review

Gudrun Piringer; Jörn Decker; Josef Thaler; Vera Trommet; Thomas Kühr; Sonja Heibl; Konrad Dörfler

doi:10.3389/fonc.2023.1166545

Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review

Gudrun Piringer, Jörn Decker, Josef Thaler, Vera Trommet, Thomas Kühr, Sonja Heibl, Konrad Dörfler

Department of Internal Medicine 3 - Hematology and Internal Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	1166545
Number of pages	8
Journal	Frontiers in oncology
Volume	13
DOIs	https://doi.org/10.3389/fonc.2023.1166545
Publication status	Published - May 2023

Fields of science

302024 Haematology
302055 Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fonc.2023.1166545

Cite this

Piringer, G., Decker, J., Thaler, J., Trommet, V., Kühr, T., Heibl, S., & Dörfler, K. (2023). Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review. Frontiers in oncology, 13, Article 1166545. https://doi.org/10.3389/fonc.2023.1166545

@article{f166a62593fd45ee89281f0d6a0521ff,

title = "Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review",

author = "Gudrun Piringer and J{\"o}rn Decker and Josef Thaler and Vera Trommet and Thomas K{\"u}hr and Sonja Heibl and Konrad D{\"o}rfler",

year = "2023",

month = may,

doi = "10.3389/fonc.2023.1166545",

language = "English",

volume = "13",

journal = "Frontiers in oncology",

}

Piringer, G, Decker, J, Thaler, J, Trommet, V, Kühr, T, Heibl, S & Dörfler, K 2023, 'Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review', Frontiers in oncology, vol. 13, 1166545. https://doi.org/10.3389/fonc.2023.1166545

Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review. / Piringer, Gudrun; Decker, Jörn; Thaler, Josef et al.
In: Frontiers in oncology, Vol. 13, 1166545, 05.2023.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review

AU - Piringer, Gudrun

AU - Decker, Jörn

AU - Thaler, Josef

AU - Trommet, Vera

AU - Kühr, Thomas

AU - Heibl, Sonja

AU - Dörfler, Konrad

PY - 2023/5

Y1 - 2023/5

UR - https://www.scopus.com/pages/publications/85159909700

U2 - 10.3389/fonc.2023.1166545

DO - 10.3389/fonc.2023.1166545

M3 - Article

VL - 13

JO - Frontiers in oncology

JF - Frontiers in oncology

M1 - 1166545

ER -

Piringer G, Decker J, Thaler J, Trommet V, Kühr T, Heibl S et al. Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review. Frontiers in oncology. 2023 May;13:1166545. doi: 10.3389/fonc.2023.1166545

Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review

Fields of science

UN SDGs

Access to Document

Other files and links

Cite this